Interchangeability and substitution of biosimilars: is health technology assessment (HTA) a tool for decision-making?

Cad Saude Publica. 2019 Sep 16;35(9):e00087219. doi: 10.1590/0102-311X00087219.

[Article in English, Portuguese]

Authors

Bruna de Oliveira Ascef^{1

2}, Renan Gonçalves Leonel da Silva¹, Haliton Alves de Oliveira Júnior², Patrícia Coelho De Soárez¹

Affiliations

¹ Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil.
² Centro Internacional de Pesquisa, Hospital Alemão Oswaldo Cruz, São Paulo, Brasil.

PMID: 31531516
DOI: 10.1590/0102-311X00087219

No abstract available

MeSH terms

Biosimilar Pharmaceuticals / standards*
Brazil
Decision Making*
Health Policy*
Humans
Technology Assessment, Biomedical / standards*

Substances

Biosimilar Pharmaceuticals